(September 19, 2019) While harnessing the immune system has resulted in strong responses for a subset of cancer patients, the majority of patients have remained unresponsive to this approach. In order to enable ovarian cancer patients to benefit from immunotherapy, Dr. Michael Goldberg’s research sought to understand how standard-of-care chemotherapy influences immune cells around the … Continued
It’s important for everyone to know the symptoms and risk factors for ovarian cancer. If you or someone you know are experiencing any of the symptoms listed below, take notice and take it seriously—and also know that their presence does not automatically indicate ovarian cancer. Take our ovarian cancer quiz: Want to deepen your understanding … Continued
(September 10, 2019) Ovarian clear-cell carcinoma is an aggressive form of ovarian cancer. Endometriosis is derived from the uterine endometrium and is a known risk factor for ovarian clear-cell carcinoma. Evidence supports ovarian clear-cell origins in the uterine endometrium. It has been known for years that co-occurring cellular mutations are observed in ovarian clear-cell carcinoma, … Continued
(September 5, 2019) OCRA funded investigator Dmitriy Zamarin, MD, PhD contributed to a study that provides an intriguing hypothesis that mutation in genes like SMARCA4 may improve tumor recognition by the immune system. The body’s immune system plays a major role in controlling tumor growth. Specialized immune cells called T-cells identify cancer cells as “foreign” … Continued
Every September, we come together to shine a spotlight on ovarian cancer, spread awareness, and raise critical funds for research and patient support. How you can help during Ovarian Cancer Awareness Month: Give to ovarian cancer research and support Your support has a direct impact in funding new research and programs that support survivors and … Continued
(August 22, 2019) This week, The US Preventive Services Task Force published new recommendations on risk assessment, genetic counseling, and genetic testing for BRCA mutations and BRCA-related cancers. The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases … Continued
(August 20, 2019) A new direction for research in ovarian cancer was brought to light last month thanks to a study published in Lancet Oncology. Researchers led by Dr. Nuno R. Nené of the University College London are investigating the role of microbiota in an individual’s risk of developing cancer. “The application of vaginal suppositories … Continued
(August 21, 2019) Every 23 minutes, another woman in the U.S. hears the words “You have ovarian cancer” for the first time. Because ovarian cancer symptoms can be subtle and attributed to other factors, diagnosis often comes as a surprise. And along with it comes a host of overwhelming information, decisions to be made, and … Continued
(July 26, 2019) OCRA grantee Michael Yaffe, MD, PhD, led a study published earlier this month in Cell Systems which found success targeting cancer cells by combining two existing classes of drugs. Dr. Yaffe and colleagues found that this combination, which targets the cancer cells’ ability to divide, dramatically increases the drug’s capacity to kill … Continued
Couldn’t make it to our National Conference? Watch our expert presentations LIVE! For the first time, we live streamed all general sessions, so you can watch as our expert speakers present the latest ovarian cancer updates, from wherever you are. These broadcasts will remain available for viewing for a limited period of time following the original … Continued
(June 19, 2019) In an interview with SurvivorNet, OCRA President and CEO Audra Moran offers some guidance to women who are battling ovarian cancer: #1 – You don’t need to go through it alone. OCRA’s Woman to Woman program matches gynecologic cancer patients with trained survivor volunteers to provide support and mentoring to women when … Continued
(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian cancer. Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options … Continued
Get email updates about research news, action alerts, and ways to join the fight.
